Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 May;20(2 Suppl):24-39.
doi: 10.1353/hpu.0.0156.

A descriptive analysis of state legislation and policy addressing clinical trials participation

Claudia R Baquet  1 , Shiraz I Mishra, Armin D Weinberg
Affiliations
Review

A descriptive analysis of state legislation and policy addressing clinical trials participation

Claudia R Baquet et al. J Health Care Poor Underserved. 2009 May.

Abstract

Objectives: This report describes state policy and legislation related to clinical trials participation and Maryland's model to enhance clinical trial availability and participation.

Methods: Descriptive review of state policy and legislation related to coverage for clinical trials costs based on data from the National Cancer Institute (NCI) State Cancer Legislative Database, the American Cancer Society, and NCI; additionally, discussion of Maryland's comprehensive multilevel clinical trial model comprising policy initiatives, community engagement, research, education, and infrastructure support.

Results: Twenty-four states have mandated clinical trial coverage through specific legislation or agreements since 1994. Covered benefits varied among the states.

Conclusions: Besides cost and insurance barriers, there is a need to address important patient, physician and researcher, and structural barriers to clinical trial participation. Maryland provides a comprehensive model to address the multi-faceted clinical trial participation determinants as it tracks state and federal policy, documents trial barriers, and conducts community education.

PubMed Disclaimer

References

    1. Comis RL, Miller JD, Aldigé CR, et al. Public attitudes towards participation in cancer clinical trials. J Clin Oncol. 2003 Mar 1;21:830–5. - PubMed
    1. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs afect accrual to cancer treatment trials. J Clin Oncol. 2002 Apr 15;20(8):2109–17. - PubMed
    1. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004 Jun 9;291(22):2720–6. - PubMed
    1. Baquet CR. Implications for cancer prevention and control through a statewide health network. Presented at: Governor's Conference on Cancer Disparities in Maryland; Baltimore, MD. Jul 2000.
    1. American Society of Clinical Oncology. Coverage of routine patient care costs in clinical trials: position statement. Alexandria, VA: American Society of Clinical Oncology; Mar, 2005. Available at: www.asco.org/

Publication types

MeSH terms